
price close busi februari
biomed devic servic
strong momentum loom
horizon maintain buy pt
bottom line unequivoc strong finish year
deliv record new patient addit robust global revenu growth said
expect remain battleground stock least given
view binari investor sentiment regard competit product launch expect
share volatil continu next sever quarter libr like garner
posit mindshar earli day us launch need launch
fulli respond competit sum despit overhang competit
launch continu think grow mid-to-high teen
beyond support view technolog superior product pipelin
expand end market consensu revenu continu view
risk/reward favor stick buy
result post revenu y/i slightli
preliminari result announc earli januari top-lin strength
support ou growth y/i out-performance vs estim driven
strong us growth y/i specif us sale benefit record growth
us commerci channel backlog medicar patient eas allow
sale forc refocu commerci patient addit manag note dtc
advertis includ libr help drive broader patient awar cgm
gross margin well ahead estim improv
y/i compani benefit higher expect us sensor sale mix
adjust ep came well cg/consensu
medicar continu support growth remind began billing/ship
medicar pipelin mid-juli receiv first payment
manag longer break medicar contribut sale
highlight continu convers compani medicar backlog contributor
strong us growth estim medicar convers remind
market repres medicar patient patient repres
addit upsid net-net encourag continu execut patient
demand expect materi driver y/i us patient growth
ou growth y/i manag highlight strong growth ou driven
improv reimburs well strength key direct sale channel
germani uk canada germani manag note end in-lin
goal cover live expect market access continu improv
global ou result especi encourag given success
key competitor abbott ou market
pipelin updat manag reiter commit enter us market
no-calibr version launch like come ada
june remind new featur simplifi applic wear
no-calibr reduc form factor new receiv transmitt view
signific posit support strong competit sell point vs libr
pair real-tim predict cgm longer term verili continu make
progress howev calibr product clearli focu near term
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
announc revenu y/i slightli
preliminari result announc earli januari higher us commerci revenu
gross margin slightli ahead estim ep
well ahead our/consensu estim rel
expect ep beat driven lower expect spend
 quarter
chang estim
reiter revenu guidanc y/i
manag expect growth support sensor volum ou
expans ww instal base expect grow faster
overal revenu gross margin expect rang
opex expect increas y/i made follow
chang estim
adjust revenu estim
lp estim
adjust revenu estim
lp estim
adjust revenu estim
lp estim
adjust revenu estim
ep estim
adjust revenu estim
lp estim
adjust revenu estim
ep estim
adjust revenu estim
ep estim
buy unchang target price februari
biomed devic servic
resultsactualcg estbeat/miss beat/miss consensusbeat/miss product revenu total gross oper result categoryactualcg estbeat/missbeat/miss prior yeary/i growthnet sale
figur summari estim revis
high-growth med-tech comp group current trade mean ev/sal multipl
estim revenu sum increas price target
base valuat ev/sal multipl appli
revenu estim price target assum cash
debt share outstand
figur matrix discount rate impli share price target
buy unchang target price februari
biomed devic servic
oldnew oldnew oldnew revenu comp ev/sal multipl price metric use ev/sal valuat growth medic devic ev/sal multipl sale share outstand figur dexcom incom statement
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price februari
biomed devic servic
canaccord genuiti estim compani report compani report
buy unchang target price februari
biomed devic servic
